To evaluate the impact of preoperative chemoradiation on sphincter preservation in patients with low- medium locally advanced resectable rectal cancer treated by four chemoradiation schedules.
Materials and Methods
Between 1990 and 2002, 247 patients were treated according to four schedules of chemoradiotherapy: FUMIR (5-fluorouracil, mitomycin, external beam radiotherapy 37.8 Gy), PLAFUR (cisplatinum, 5-fluorouracil, external beam radiotherapy 50.4 Gy), TOMRT (raltitrexed, external beam radiotherapy 50.4 Gy), and TOMOXRT (raltitrexed, oxaliplatin, external beam radiotherapy 50.4 Gy). Four to five weeks after chemoradiation, patients were restaged and surgery was performed 2-3 weeks later.
Results
Overall, the sphincter-saving surgery was performed in 82.5% of patients. In patients candidate to an abdominoperineal resection before chemoradiaton (distance tumor-anorectal ring, <30 mm) a sphincter-saving surgery was possible in 58% of cases: 44% (FUMIR), 52% (PLAFUR), 63% (TOMRT), 76% (TOMOXRT) (P <0.017). The involved surgeons kept the same surgical criteria in performing sphincter-saving surgery. After chemoradiation, patients with tumor location still between 0 and 30 mm received sphincter-saving surgery according to the protocols: 33% (FUMIR), 42% (PLAFUR), 50% (TOMRT), 64% (TOMOXRT) (P = 0.066)
Conclusions
Even though the surgeons’ skill in performing sphincter-saving surgery could be improved with time, the high rate of this procedure in the latest schedules suggests an impact of the new drugs in promoting tumor downsizing and therefore sphincter-saving surgery.
SauerR., BeckerH., HohenbergerW., RodelC., WittekindC., FietkauR., MartusP., TschmelitschJ., HagerE., HessC.F., KarstensJ.H., LierschT., SchmidbergerH., RaabR.: German Rectal Cancer Study Group: Preoperative versus postoperative chemoradiotherapy for rectal cancer.N Engl J Med, 351: 1731–1740, 2004.
2.
BossetJ.F., CalaisG., MineurL., MaingonP., Radosevic-JelicL., DabanA., BardetE., BenyA., OllierJ.C., ColletteL.: Preoperative radiotherapy (Preop RT) in rectal cancer: effect and timing of additional chemotherapy (CT) 5 year results of the EORTC 22921 trial.J Clin Oncol,23(16S), Part I of II (June I Suppl): 3505, 2005.
3.
GerardJ., BonnetainF., ConroyT., ChapetO., BoucheO., Closon-DejardinM., UntereinerM., LeducB., FrancoisE., BedenneL.: Preoperative (preop) radiotherapy (RT) + 5-fluorouracil/folinic acid in T3-4 rectal cancers: results of the FFCD 9203 randomized trial.J Clin Oncol,23(16S), Part I of II (June 1 Suppl): 3504, 2005.
ValentiniV., CocoC., CelliniN., PicciocchiA., RosettoM.E., MantiniG., MarmiroliL., BarbaroB., CogliandoloS., NuzzoG., TedescoM., Ambesi ImpiombatoF., CosimelliM., RotmanM.: Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation.Int J Radiat Oncol Biol Phys, 45: 1175–1184, 1999.
6.
ValentiniV., DogliettoG.B., MorgantiA.G., TurrizianiA., SmaniottoD., De SantisM., RattoC., SofoL., CelliniN.: Preoperative chemoradiation with raltitrexed for T2/N + and T3/N + rectal cancers: a phase I study.Eur J Cancer, 37: 2050–2055, 2001.
7.
GambacortaM.A., ValentiniV., MorgantiA.G., MantiniG., MiccichèF., RattoC., Di MiceliD., RotondiF., AlfieriS., DogliettoG.B., VargasJ.G., De PaoliA., RossiC., CelliniN.: Chemoradiation with raltitrexed (Tomudex) in preoperative treatment of stage II-III resectable rectal cancer: a phase II study.Int J Radiat Oncol Biol Phys, 60: 130–138, 2004.
8.
GambacortaM.A., ValentiniV., CocoC., MorgantiA.G., SmaniottoD., MiccichèF., MantiniG., BarbaroB., Garcia-VargasJ.E., MagistrelliP., PicciocchiA., CelliniN.: Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: a phase I and II study.Int J Radiat Oncol Biol Phys;, 60: 139–148, 2004.
9.
UICC International Union Against Cancer TNM Classification of Malignant Tumours, Fourth Edition, 2nd Revision, Springer Verlag, 1992.
10.
MaranoP., BarbaroB., De FrancoA., VecchioliA., CelliniN., ValentiniV., CocoC., DogliettoG.B., VecchioF.M.: Diagnostic and therapeutic integration in rectal cancer. Preliminary notes.Radiol Med (Torino), 84: 261–273, 1992.
11.
International Commission on Radiation Units and Measurements. ICRU Report 50: Prescribing, recording and reporting photon beam therapy, 1993.
12.
International Commission on Radiation Units and Measurements. ICRU Report 62: prescribing, recording and reporting photon beam therapy (supplement to ICRU Report 50), 1999.
13.
CapirciC., PolicoC., MandolitiG.: Dislocation of small bowel volume within box pelvic treatment fields, using new “up down table” device.Int J Radiat Oncol Biol Phys, 51: 465473, 2001.
14.
SofoL., RattoC., DogliettoG.B., ValentiniV., TrodellaL., IppolitiM., NuceraP., MericoM., BellantoneR., BossolaM., CelliniN., CrucittiF.: Intraoperative radiation therapy in integrated treatment of rectal cancers. Results of phase II study.Dis Colon Rectum, 39: 1396–1403, 1996.
15.
MachoverD., SchwarzenbergL., GoldschmidtE., TouraniJ.M., MichalskiB., HayatM., DorvalT., MissetJ.L., JasminC., MaralR., MatheG.: Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study.Cancer Treat Rep, 66: 1803–1807, 1982.
16.
MillerA.B.: Reporting result of cancer treatment.Cancer, 47: 207–214, 1981.
MinskyB.D., CohenA.M., EnkerW.E., SigurdsonE.: Phase I/II trial of pre-operative radiation therapy and coloanal anastomosis in distal invasive resectable rectal cancer.Int J Radiat Oncol Biol Phys, 23: 387–392, 1992.
19.
BrownM.B., BenedettiJ.K.: Sampling behavior of tests for correlation in two-way contingency tables.J Am Stat Assoc, 72: 309–315, 1977.
20.
CochranW.G.: Some methods for strengthening the common chi2 tests.Biometrics, 10: 417–441, 1954.
21.
CoxD.R.: Regression model and life tables.J Royal Stat Soc Series B, 34: 187–220, 1972.
22.
HosmerD.W., TaberS., LemeshowS.: The importance of assessing the fit of logistic regression models: a case study.Am J Public Health, 81: 1630–1635, 1991.
23.
GrafW., DahlbergM., OsmanM.M., HolmbergL., PahlmanL., GlimeliusB.: Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients.Radiother Oncol, 43: 133–137, 1997.
24.
MarijnenC.A., NagtegaalI.D., Klein KranenbargE., HermansJ., van de VeldeC.J., LeerJ.W., Van KriekenJ.H.: Pathology Review Committee and the Cooperative Clinical Investigators. No downstaging after short-term preoperative radiotherapy in rectal cancer patients.J Clin Oncol, 19: 1976–1984, 2001.
25.
BujkoK., NowackiM.P., Nasierowska-GuttmejerA., MichalskiW., BebenekM., PudelkoM., KryjM., OledzkiJ., SzmejaJ., SluszniakJ., SerkiesK., KladnyJ., PamuckaM., KukolowiczP.: Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomized trial comparing short-term radiotherapy vs conventionally fractionated radiochemotherapy.Radiother Oncol, 72: 15–24, 2004.
26.
HyamsD.M., MamounasE.P., PetrelliN., RocketteH., JonesJ., WieandH.S., DeutschM., WickerhamL., FisherB., WolmarkN.: A clinical trial to evaluate the worth of preoperative multi-modality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03.Dis Colon Rectum, 40: 131139, 1997.
27.
WagmanR., MinskyB.D., CohenA.M., GuillemJ.G., PatyP.P.: Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up.Int J Radiat Oncol Biol Phys, 42: 51–57, 1998.
28.
CraneC.H., SkibberJ.M., FeigB.W., VautheyJ.N., ThamesH.D., CurleyS.A., Rodriguez-BigasM.A., WolffR.A., EllisL.M., DelclosM.E., LinE.H., JanjanN.A.: Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma.Cancer, 97: 517–524, 2003.
29.
KirwanW.O., TurnbullR.B.Jr., FazioV.W., WeakleyF.L.: Pullthrough operation with delayed anastomosis for rectal cancer.Br J Surg, 65: 695–699, 1978.
30.
Luna PerezP., Rodriguez RamirezS., Hernandez PachecoF., Gutierrez De La BarreraM., FernandezR., LabastidaS.: Anal sphincter preservation in locally advanced low rectal adenocarcinoma after preoperative chemoradiation therapy and coloanal anastomosis.J Surg Oncol, 82: 3–9, 2003.
31.
KuvshinoffB., MaghfoorI., MiedemaB., BryerM., WestgateS., WilkesJ., OtaD.: Distal margins requirements after preoperative chemoradiotherapy for distal rectal carcinoma: are < 1 cm sufficient?Ann Surg Oncol,8: 163–169, 2001.
DupuisO., ViéB., LledoG., HennequinC., NoirclercM., BennamounM., PavlovitchJ.M., JacobJ.H.: Capecitabine (X) chemoradiation (CRT) in the preoperative treatment of patients (pts) with rectal adenocarcinoma: A phase II GERCOR trial.J Clin Oncol,14(July 15 Suppl): 3538, 2004.
34.
BlackstockW., TepperJ.E., Douglas CaseL.: In vitro and in vivo radiosensitization of colon cancer cells by cis-[(1R,2R)-1-2-cyclohexanediamine-N,N’] [oxalato(2-)-OO] platinum (oxaliplatin).Int J Mol Med,10(Suppl 1): S68, 2002.
35.
GerardJ.P., ChapetO., NemozC., RomestaingP., MornexF., CoquardR., BarbetN., AtlanD., AdeleineP., FreyerG.: Pre-operative concurrent chemoradiotherapy in locally advanced rectal cancer with high dose radiation and oxaliplatin containing regimen: the Lyon R0-04 phase II trial.J Clin Oncol, 21: 1119–1124, 2003.
36.
RodelC., GrabenbauerG.G., PapadopoulosT., HohenbergerW., SchmollH.J., SauerR.: Phase I/II trial of capecitabine, oxaliplatin and radiation for rectal cancer.J Clin Oncol, 21: 3098–3104, 2003.
37.
MehtaV.K., ChoC., FordJ.M., JambalosC., PoenJ., KoongA., LinA., BastidasJ.A., YoungH., DunphyE.P., FisherG.: Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil and weekly CPT11, followed by surgery for ultrasound-staged T3 rectal cancer.Int J Radiat Oncol Biol Phys, 55: 132–137, 2003.
38.
TempleL.K., WongW.D., MinskyB.: The impact of radiation on functional outcomes in patients with rectal cancer and sphincter preservation.Semin Radiat Oncol, 13: 469–477. 2003.
39.
KollmorgenC.F., MeagherA.P., WolffB.G., PembertonJ.H., MartensonJ.A., IllstrupD.M.: The long term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function.Ann Surg, 220: 676–682, 1994.
40.
ValeroG., LujanJ.A., HernandezQ., De Las HerasM., PellicerE., SerranoA., ParrillaP.: Neoadjuvant radiation and chemotherapy in rectal cancer does not increase postoperative complications.Int J Colorectal Dis, 18: 495–499, 2003.
41.
RouanetP., Saint AubertB., LemanskiC., SenesseP., GourgouS., QuenetF., YcholuM., KramarA., DuboisJ.: Restorative and non restorative surgery for low rectal cancer after high-dose radiation: long term oncologic and functional results.Dis Colon Rectum, 45: 305–313, 2002.
42.
ValentiniV., CocoC., CelliniN., PicciocchiA., FaresM.C., RosettoM.E., MantiniG., MorgantiA.G., BarbaroB., CogliandoloS., NuzzoG., TedescoM., Ambesi ImpiombatoF., CosimelliM., RotmanM.: Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response and sphincter preservation in three consecutive studies.Int J Radiat Oncol Biol Phys, 51: 371–383, 2001.
43.
GrumannM.M., NoackE.M., HoffmanI.A.: Comparison of quality of life in patients undergoing abdominoperineal extirpation or anterior resection for rectal cancer.Ann Surg, 233: 149156, 2001.
44.
GlimeliusB., GronbergH., JarhultJ., WallgrenA., Cavallin StahlE.: A systematic overview of radiation therapy effects in rectal cancer.Acta Oncol, 42: 476–492, 2003.
